Our analysis

Analysis for your
next decision.

Competitive landscapes, target product profiles, and conference intelligence. Our AI agents and scientists work together to deliver analysis tailored to your decision.

Complete analysis Sources traceable Scientist reviewed Scheduled updates available

Available today

Finished analysis.
Scientific judgment throughout.

Dashboards, reports, executive decks, and structured data are delivery formats. The analysis itself is what you purchase.

01 / Competitive intelligence

Competitive landscapes

A scientist-reviewed analysis of competitors, assets, clinical programs, catalysts, evidence gaps, and the implications for portfolio decisions.

Decision: Where should we place the next portfolio bet, and what could change that choice?
Evidence included: Asset and company records, clinical programs, trial data, catalysts, regulatory sources, and relevant market evidence.
What you receive: Competitive landscape, asset profiles, trial matrix, gap analysis, strategic implications, and evidence register.
Available formats: Interactive dashboard, report, executive deck, and structured output.
Update model: Scheduled updates on an agreed cadence.

Line-to-line attrition (single US RWE cohort; not a universal epidemiologic constant) 1L → 2L (switch rate) 46% 2L → 3L 33% Patients <70 bridging to 2L 43% ~55–62% exit the pipeline entirely between lines — rapid decline, toxicity, or early mortality. Neoadjuvant: 57% of localized patients never reach surgery (progression 22%, occult mets 21%, decline 11%). — See the real-world patterns behind the opportunity.

02 / Product strategy

Target product profiles

A structured, evidence-backed product strategy connecting the target profile to competitive benchmarks, standards of care, positioning choices, and strategic options.

Decision: How should the asset differentiate, and which profile can the evidence support?
Evidence included: Current and future standards of care, competitor profiles, endpoints, trial designs, regulatory context, and market evidence.
What you receive: Structured TPP, competitive benchmarks, positioning analysis, evidence appendix, and strategic options.
Available formats: Structured profile, interactive dashboard, detailed report, executive deck, and structured data.
Update model: Scheduled updates on an agreed cadence.

–2.6 hrs/day Onapgo (apomorphine) Largest reported reduction in symptom-return time on this endpoint among device-aided or oral therapies, vs. 0.9 hrs with placebo. DEVICE-AIDED +1.74 hrs/dose Crexont (carbidopa/levodopa) Largest reported per-dose gain in well-controlled symptom-control time among oral therapies (~70% increase), with fewer daily doses. ORAL ADJUNCT — Clinical benchmarks that make differentiation concrete.

03 / Evidence intelligence

Conference intelligence

An ongoing program that turns high-volume scientific and medical information into conference readiness, evidence updates, and implications your team can use.

Decision: What changed, which signals matter, and how should our positioning or priorities respond?
Evidence included: Abstracts, posters, presentations, trial records, competitor updates, regulatory events, and relevant publications.
What you receive: Conference readiness pack, SWOT analysis, executive summary, evidence update, and post-conference implications.
Available formats: Interactive dashboard, evidence register, report, executive briefing, and structured output.
Update model: Managed across the agreed conference calendar.

ANTIBODY-DRUG CONJUGATE Vantrell + Okemo $9.2B DEAL VALUE Rights to a conjugate pipeline — among the largest transactions of the year in the category.; ACQUISITION Marrowgate + Kessel $6.5B $3.0B UPFRONT Adds cell-therapy manufacturing and a genetic medicines platform ahead of a confirmatory readout. — Keep the competitive picture current as new evidence and deals emerge.

Choose the starting point

Choose the analysis your decision needs.

Strategic questions, matching deliverables, included outputs, and update models
Buyer question	Strategic deliverable	Included outputs	Update model
Where should we place the next portfolio bet?	Competitive landscape	Asset profiles, trial matrix, implications	Agreed cadence
How should the asset differentiate?	Target product profile	Benchmarks, positioning, strategic options	Agreed cadence
What changed at the conference?	Conference intelligence	Readiness pack, update, executive summary	Conference cycle

Within an engagement

Keep the analysis current.

We agree the cadence with your team. Epistemic incorporates new evidence, life-science experts review the changes, and the work is updated for the next decision cycle.

01Initial analysis provided
02New evidence gathered for the agreed review
03Scientists inspect changes and implications
04Updated analysis provided

Scheduled updates sequence from strategic question to scientist-reviewed deliverable and agreed update cycle.

Platform vision

Build on the evidence behind each answer.

Epistemic is building the connected intelligence platform that will use the evidence behind each answer, make subsequent strategic questions faster to address, and make more possibilities practical to explore.

Reusable evidence foundation Gather once. Connect over time.

More assets More indications More scenarios More hypotheses

Talk to our team

What decision is
your team facing?

Bring us your question. Together, we’ll define the analysis you need.